Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Control of Atm-/- thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone.

Kuang X, Yan M, Liu N, Scofield VL, Qiang W, Cahill J, Lynn WS, Wong PK.

Cancer Chemother Pharmacol. 2005 Mar;55(3):203-12. Epub 2004 Nov 27.

PMID:
15570424
2.

Prevention of thymic lymphoma development in Atm-/- mice by dexamethasone.

Yan M, Kuang X, Qiang W, Shen J, Claypool K, Lynn WS, Wong PK.

Cancer Res. 2002 Sep 15;62(18):5153-7.

3.

The glucocorticoid receptor is increased in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells, and its nuclear translocation counteracts c-myc expression.

Yan M, Kuang X, Scofield VL, Shen J, Lynn WS, Wong PK.

Steroids. 2007 May;72(5):415-21. Epub 2007 Mar 12.

PMID:
17418878
4.

Rag-dependent and Rag-independent mechanisms of Notch1 rearrangement in thymic lymphomas of Atm(-/-) and scid mice.

Tsuji H, Ishii-Ohba H, Noda Y, Kubo E, Furuse T, Tatsumi K.

Mutat Res. 2009 Jan 15;660(1-2):22-32. doi: 10.1016/j.mrfmmm.2008.10.002. Epub 2008 Oct 21.

PMID:
19000702
5.

Deregulation of mTOR signaling is involved in thymic lymphoma development in Atm-/- mice.

Kuang X, Shen J, Wong PK, Yan M.

Biochem Biophys Res Commun. 2009 Jun 5;383(3):368-72. doi: 10.1016/j.bbrc.2009.04.019. Epub 2009 Apr 11.

PMID:
19364503
6.

Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Baltimore D.

Genes Dev. 1996 Oct 1;10(19):2411-22.

7.

Atm knock-in mice harboring an in-frame deletion corresponding to the human ATM 7636del9 common mutation exhibit a variant phenotype.

Spring K, Cross S, Li C, Watters D, Ben-Senior L, Waring P, Ahangari F, Lu SL, Chen P, Misko I, Paterson C, Kay G, Smorodinsky NI, Shiloh Y, Lavin MF.

Cancer Res. 2001 Jun 1;61(11):4561-8.

8.

ATM controls c-Myc and DNA synthesis during postnatal thymocyte development through regulation of redox state.

Yan M, Zhu C, Liu N, Jiang Y, Scofield VL, Riggs PK, Qiang W, Lynn WS, Wong PK.

Free Radic Biol Med. 2006 Aug 15;41(4):640-8. Epub 2006 May 22.

PMID:
16863997
9.

Ataxia telangiectasia gene mutations in leukaemia and lymphoma.

Boultwood J.

J Clin Pathol. 2001 Jul;54(7):512-6. Review.

10.
11.

Reactive oxygen species abrogate the anticarcinogenic effect of eicosapentaenoic acid in Atm-deficient mice.

Schubert R, Reichenbach J, Koch C, Kloess S, Koehl U, Mueller K, Baer P, Beermann C, Boehles H, Zielen S.

Nutr Cancer. 2010;62(5):584-92. doi: 10.1080/01635580903532457.

PMID:
20574919
12.

RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice.

Petiniot LK, Weaver Z, Vacchio M, Shen R, Wangsa D, Barlow C, Eckhaus M, Steinberg SM, Wynshaw-Boris A, Ried T, Hodes RJ.

Mol Cell Biol. 2002 May;22(9):3174-7.

13.

Regulation of radiation-induced protein kinase Cdelta activation in radiation-induced apoptosis differs between radiosensitive and radioresistant mouse thymic lymphoma cell lines.

Nakajima T, Yukawa O, Tsuji H, Ohyama H, Wang B, Tatsumi K, Hayata I, Hama-Inaba H.

Mutat Res. 2006 Mar 20;595(1-2):29-36.

PMID:
16337250
14.
15.

atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity.

Westphal CH, Rowan S, Schmaltz C, Elson A, Fisher DE, Leder P.

Nat Genet. 1997 Aug;16(4):397-401.

PMID:
9241281
16.

Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice.

Bagley J, Cortes ML, Breakefield XO, Iacomini J.

Blood. 2004 Jul 15;104(2):572-8. Epub 2004 Mar 25.

17.

Persistence of unrepaired DNA double strand breaks caused by inhibition of ATM does not lead to radio-sensitisation in the absence of NF-κB activation.

Veuger SJ, Durkacz BW.

DNA Repair (Amst). 2011 Feb 7;10(2):235-44. doi: 10.1016/j.dnarep.2010.11.005. Epub 2010 Dec 8.

PMID:
21144805
18.

Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL.

Luo L, Lu FM, Hart S, Foroni L, Rabbani H, Hammarström L, Yuille MR, Catovsky D, Webster AD, Vorechovský I.

Cancer Res. 1998 Jun 1;58(11):2293-7. Erratum in: Cancer Res 1998 Aug 1;58(15):3488.

19.

Supplemental Content

Support Center